The treatment landscape for EGFR-mutated NSCLC is rapidly evolving, offering a diverse array of therapeutic choices that can be strategically integrated into a patient’s treatment journey. With the recent FDA approval of Dato-DXd, there is a new therapeutic avenue for patients who have previously received EGFR-directed therapy and chemotherapy.
This expansion in treatment options introduces greater complexity into clinical decision-making, emphasizing the need for multidisciplinary tumor boards and expert consultation to navigate the intricate treatment pathways effectively. From first-line options like osimertinib monotherapy to combination regimens like FLAURA2 and the MARIPOSA regimen, each choice in treatment influences subsequent lines of therapy and overall patient outcomes. Understanding the evolving landscape of EGFR+ NSCLC treatment is crucial for healthcare professionals and patients alike.
Read more from targetedonc.com